Announcement under Regulation 30 (LODR)- Credit Rating

AHCL/ SE/20/2026-27 5 August 2026 The National Stock Exchange of India BSE Limited Limited Department of Corporate Services “Exchange Plaza”, C-1, Block G 1st Floor, P.J. Towers, Dalal Street, Bandra-Kurla Complex, Bandra (E) Mumbai 400 001 Mumbai 400 051 ISIN: INE098F01031 Symbol : AMRUTANJAN Scrip Code: 590006 Dear Sir/ Madam, Sub.: Intimation on Credit Rating Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 [“Listing Regulations”], this is to inform that CARE Ratings Limited (“CARE”) has assigned credit ratings for the Company as per below: Facilities/Instruments Amount Rating Rating Action Issuer rating Nil Care A; Stable Assigned Further, pursuant to regulation 46 of Listing Regulations, the reaffirmation of credit rating is available on the company’s website www.amrutanjan.com. Kindly take the same on your record. Thanking You, Yours faithfully For Amrutanjan Health Care Limited (Gagan Preet Singh) General Manager - Legal Company Secretary & Compliance Officer Amrutanjan Health Care Limited I 03, (Old No. 42-45), Luz Church Road, E-mail :customercare@amrutanjan.com Mylapore, Chennai - 600 004 WebSite : www. amrutanjan.com Tamil Nadu, India. Toll Free No.: I • 800 - 425 - 4545 Tel :+91-44 - 2499 4465 CIN-L24231TN1936PLC000017 +91-44 • 2466 9000 Fax :+91-44 - 2499 4585 Press Release Amrutanjan Health Care Limited July 31, 2026 Facilities/Instruments Name of the Regulator1 Amount (₹ crore) Rating2 Rating Action Issuer rating - 0.00 CARE A; Stable Assigned Details of instruments/facilities in Annexure-1. There is no instrument being rated and hence, Regulator of the Instrument is not applicable. Rating scale and definitions are being followed as stipulated in Securities and Exchange Board of India (SEBI) Master Circular for Credit Rating Agencies (CRAs). Rationale and key rating drivers The rating assigned to Amrutanjan Health Care Limited (AHCL) derives strength from its established century-long track record of operations, strong brand recall in the over-the-counter (OTC) pain relief segment with newer brands supporting diversification, extensive distribution network supporting wide geographic reach, debt-free capital structure and comfortable liquidity, and healthy operating margins despite subdued profitability in newer businesses. However, ratings are constrained by the company’s modest scale of operations in relation to the industry with product concentration in the pain relief segment, margins susceptible to raw material price volatility, and intense competition in the fast- moving consumer goods (FMCG) sector. Rating sensitivities: Factors likely to lead to rating actions Positive factors • Sustained growth in scale of operations to over ₹1000 crore while maintaining healthy operating margins. Negative factors • Decline in operating income below ₹400 crore and drop in profitability. • Significant debt-funded capex impacting the financial risk profile, leading to overall gearing above 0.50x. Analytical approach: Standalone Outlook: Stable The “stable” outlook reflects CARE Ratings Limited’s (CareEdge Ratings’) expectation that AHCL is expected to sustain its operational performance in the medium term supported by its product portfolio of established brands, while maintaining a healthy financial risk profile aided by adequate accruals, and limited reliance on debt. Detailed description of key rating drivers Key strengths Established track record of operations of over a century AHCL has an established presence in the Indian healthcare and personal care industry, with a legacy spanning 133 years. Founded in 1893 by K Nageswara Roa Pantulu with its flagship Amrutanjan Pain Balm, the company has built one of the country’s oldest and well recognised consumer healthcare brands. Led by multiple generations of the promoter family since its inception, the current Chairman and Managing Director, S Sambhu Prasad, represents the third generation of promoter leadership. The company has continued to enjoy strong brand recall for its flagship pain balm through the years, while diversifying into other healthcare and personal care categories, such as congestion relief, women’s hygiene, and rehydration solutions, among others. 1SEBI: Securities and Exchange Board of India; RBI: Reserve Bank of India; MCA: Ministry of Corporate Affairs; IRDAI: Insurance Regulatory and Development Authority of India; PFRDA: Pension Fund Regulatory and Development Authority. 2Complete definitions of ratings assigned are available at www.careratings.com and in other CARE Ratings Limited’s publications. 1 CARE Ratings Ltd. Press Release Strong Amrutanjan brand recall; newer brands support diversification AHCL derives a significant competitive advantage from its flagship Amrutanjan brand, which enjoys strong consumer recall and an established presence in the OTC pain relief market. The brand's established recall and customer loyalty have enabled the company to maintain stable demand despite increasing competition. As part of its long-term strategy to transform into a diversified FMCG player, the company entered the women’s hygiene segment in 2011 with trading of sanitary napkins and related hygiene products under the brand “Comfy”. In the same year, the company also acquired Fruitnik, a brand offering fruit juices and non- carbonated soft drinks and has since repositioned the brand’s focus towards fruit juices and electrolyte-infused beverages. Apart from its flagship Amrutanjan brand in the OTC pain management segment, the company's key brands include ‘Relief’ in congestion relief, ‘Comfy’ in women's hygiene, ‘Enerlyte’ and ‘Electro+’ in Oral Rehydration Solutions (ORS), and ‘Fruitnik’ in fruit-based beverages. The company launched a personal care segment in Q4FY26, with the introduction of men’s razors under brand ‘Smoothe’ and women’s razors under the existing brand ‘Comfy’. While Amrutanjan continues to be the company's most established brand, newer brands are gradually building consumer awareness and have broadened the company's portfolio across adjacent categories. Extensive distribution network supporting wide geographic reach The company benefits from an extensive distribution network supported by long-standing relationships with distributors, stockists, and retail partners, enabling widespread availability of its products through traditional and emerging channels. AHCL’s products are distributed through multiple channels including general trade, chemists, organised retail outlets, and major e-commerce and quick commerce platforms. As of March 31, 2025, the company had a dealer network of 1,656 distributors, with product presence in 1.11 million outlets pan-India. The company has a strong presence in southern states: Tamil Nadu, Karnataka, and Andhra Pradesh, and eastern states: Odisha, West Bengal, and Assam, which collectively accounted for ~60% of revenue in FY26. Debt-free capital structure AHCL maintained a healthy capital structure characterised by a strong net worth base of ₹368.78 crore as of March 31, 2026, and absence of external debt. The company’s fixed repayment obligations remained limited to lease liabilities on its office premises, while it maintained cash bank balance of ₹221.85 crore as of March 31, 2026, providing additional liquidity. AHCL set up its sanitary napkin converting plant from FY25 to FY27 at a total cost of ₹130 crore funded entirely by internal accruals and liquid funds. Gross cash accruals remained in the range of ₹50 – 65 crore in the last three years, providing adequate financial flexibility to meet its working capital requirements and planned capital expenditure. With no material debt-funded investments planned, AHCL’s capital structure is expected to remain comfortable in the medium term. Healthy operating margin despite subdued profitability in new expansions AHCL’s operating profit margin remained comfortable at 15.06% in FY26, improving from 12.98% in FY25, [Showing first 8,000 characters — download PDF for full document]